Clinical

Articles

Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.

FDA Updates Safety Label of Byetta

If insulin copays were capped at $35, Part D enrollees would save 29% on average, according to new analysis from Kaiser Family Foundation.

Study: Medicare Part D Enrollees’ Spending for Insulin Increased

Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.


FDA Okays Lilly’s Novel Diabetes Drug

Ozempic is now available in three doses to improve blood sugar in people with type 2 diabetes.




FDA Approves Higher Dose of Ozempic 

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.


Civica’s Allan Coukell Talks about Its Insulin Program

Once approved, the insulins will be available to patients for no more than $30 per vial.


Civica Plans to Sell Lower-Cost Insulins


Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.


 Walgreens Offering Biosimilar and Interchangeable Insulin Semglee



OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.




 OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary

Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.

Biocon Launches Biosimilar Semglee

Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.

Diabetes and Endocrinology